Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
about
Efficacy of antidepressantsNovel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publicationsPerformance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.Analysis of treatment effectiveness in longitudinal observational data.Patient-reported outcomes associated with use of physical therapist services by older adults with a new visit for back painA systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countriesThe impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.Pharmacoeconomic studies in Nepal: the need of the hour.Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?Modeling and simulation of adherence: approaches and applications in therapeutics.Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.The NICE ADHD health technology assessment: a review and critiqueAlvimopan Use, Outcomes, and Costs: A Report from the Surgical Care and Outcomes Assessment Program Comparative Effectiveness Research Translation Network Collaborative.A primer on critical care pharmacy services.Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?A primer on effectiveness and efficacy trialsDifferent aspects of adherence to antihypertensive treatments.Evaluating the true cost of hypertension management: evidence from actual practice.Explanatory versus pragmatic trial-based economic evaluations: application to alternative therapies for burns.Properties of patient-reported outcome measures in individuals following acute whiplash injuryEfficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.Adherence to biologic DMARD therapies in rheumatoid arthritis.Specific immunotherapy for allergic rhinitis to grass and tree pollens in daily medical practice-symptom load with sublingual immunotherapy compared to subcutaneous immunotherapy.Clinical pharmacology confounders in older adults.Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.Three-dimensional printed upper-limb prostheses lack randomised controlled trials: A systematic review.Precise definitions of some terminology for longitudinal clinical trials: subjects, patient populations, analysis sets, intention to treat, and related terms.Study control, violators, inclusion criteria and defining explanatory and pragmatic trials.Adherence to Long-Acting Bronchodilators After Discharge for COPD: How Much of the Geographic Variation is Attributable to the Hospital of Discharge and How Much to the Primary Care Providers?Pitfalls associated with commonly used methods for pharmacoeconomic analyses.Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma.Activated protein C: cost-effective or costly?Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study.Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting.Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.Clinical efficacy and effectiveness of 3D printing: a systematic review.
P2860
Q24656010-E39F866B-6F72-4760-9FB4-081BBE1E83B3Q28752005-68B7A074-E5C5-4A70-A731-E886B5A8CD8CQ30571895-515EBE0A-2D56-4C28-B6B3-CF1FE069971AQ30590794-380E5242-A222-425C-AF4A-EE905C109432Q31034242-6B15E1F1-D673-440F-AB0F-593344EB1539Q33261643-B52D040F-B106-4604-8BDC-53601CD15BDAQ33299846-7B9AC552-31CE-4230-B0F2-4318C38CC49EQ33577709-B3F005BE-760A-49C5-B299-83CF458E5E3AQ34116368-707C8DEA-9F06-4C52-BD5E-4A5C8130EB54Q34464972-F0EF36A5-8607-4767-8B0E-C5650BF6D99BQ34650925-B349857D-E2E9-4B08-B49A-80BF7282DB55Q35908186-FD0736F6-68F4-4927-9B5D-E3D98545EB16Q36341606-09CFE9F2-5CEB-4295-8D4B-ED461CD7A091Q36439111-65EC2587-E02B-4302-9071-58B1956D8819Q36491460-8A5AEA3F-C793-4006-9A3F-8D5DE474D7DDQ36845583-ECAE4405-0E8B-4306-AF08-776787DC8C2CQ37328821-A278F073-E54B-4028-8DA8-A9231A60BFA7Q37528267-8B717CEC-1DAB-44E1-ABC9-F43A9240F1F2Q37549837-9153D328-00B1-4B2A-8FB3-8D4E4C764EB3Q37609194-815B800C-810F-4BE8-9D6B-B5F10F4BAA22Q37609345-906AEE1D-C453-4137-9AC3-CF10A4A41DB5Q37685134-50F06793-E7CA-497B-B782-A1969B5669D7Q37699683-88AA0AA9-F494-46A2-B6F4-95A74820D08BQ37710168-23618393-37CE-4ABC-B7CC-A769B233B282Q37777418-4ABA1CAF-98A2-41AC-BC68-E2F9B43A5DA6Q37890414-F62524AE-2537-45FF-96DF-41107976BB1CQ38040127-F279843E-9FD5-412B-B329-A31393E4DDC9Q38492034-F198B109-A532-4557-8AE2-6BB4BE4644D5Q39398115-11075C5D-F0AD-4748-85E4-5FB6D26B2D4DQ39398920-285E5C99-5623-45A9-83BC-F6FBA6C4F7D6Q40638787-4423E4C9-9684-41C3-A49B-14F63B940746Q40649862-A1163B5B-64F8-41CF-B8FA-6BBC4570A5B2Q40661362-C0B0C444-3EDA-4634-B623-CFC5E1625C17Q42661119-18538E5A-C0C5-4B77-845F-D2159E255769Q43028980-A4EF053C-ABE4-464B-A165-1416FCC7ABE0Q43674563-CDD3E234-F969-467C-A26C-8F5BD978C601Q43744795-C6F1D976-6B15-401C-928C-F33434A5BEE6Q46827010-6C0BE3D0-6F17-4AC5-8AAA-1A0CD3924E0FQ47123282-8ABCE55C-E361-4598-AF06-6D54A800FF2CQ47223187-8DA69C70-BC59-4D4D-B77D-47CB773FEDBF
P2860
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@ast
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@en
type
label
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@ast
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@en
prefLabel
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@ast
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@en
P1433
P1476
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
@en
P2093
P304
P356
10.2165/00019053-199915050-00001
P577
1999-05-01T00:00:00Z
P6179
1016505569